Eyeing $1B annual sales, Emergent BioSolutions to buy Narcan maker Adapt for $735M
admin 29th August 2018 Uncategorised 0Hard on the heels of its $270 million deal for vaccine expert PaxVax, frequent government contractor Emergent BioSolutions is buying Adapt Pharma and its opioid overdose-reversing drug Narcan for $735 million, as the public health crisis rages on in the U.S.
More: Eyeing B annual sales, Emergent BioSolutions to buy Narcan maker Adapt for 5M
Source: fierce